Primary or secondary immunodeficiencies, immunomodulation in autoimmune diseases Haematological Disorders Other immunodeficiencies
Conditions
Interventions
Treatment with Octagam® 10% will be documented. This includes data about the patient's disease, age, gender, weight, concomitant medication or illness. For each application, the date and duration of i
Sponsors
Octapharma GmbH (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of any age and gender who receive treatment with Octagam® 10%
Exclusion criteria
Exclusion criteria: Patients with known contraindications to Octagam® 10%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To observe the tolerability of Octagam® 10% in different indication groups in routine clinical practice | — |
Secondary
| Measure | Time frame |
|---|---|
| Data about the efficacy of Octagam® 10% | — |
Countries
Germany
Outcome results
None listed